|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021311,
umls-concept:C0024398,
umls-concept:C0042196,
umls-concept:C0332157,
umls-concept:C0443252,
umls-concept:C0871261,
umls-concept:C1537056,
umls-concept:C1622204,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2587213,
umls-concept:C2911692
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2004-3-8
|
|
pubmed:abstractText |
The potential of vaccine-elicited anti-HIV envelope antibodies to control HIV-infection was evaluated by immunizing macaques with the HIV envelope protein and transiently depleting them of their CD8+ cells before intravenous challenge with the pathogenic CCR5-tropic SIV/HIV chimeric virus, SHIV(SF162P4). Although sterilizing immunity was not achieved, all vaccinated animals effectively controlled infection and remained free of disease for the duration of observation (over 3 years). In contrast, during the same period, the control animals progressed to disease. Both the vaccinees and the controls developed robust cell-mediated antiviral and neutralizing antibody responses following infection. A comparative analysis of these responses suggests that the more effective long-term control of infection by the vaccinated animals is due to the more rapid development of anti-HIV envelope antibodies. These studies suggest that priming by vaccination of B cell anti-HIV envelope responses maybe crucial for the long-term control of HIV infection.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0042-6822
|
|
pubmed:author |
pubmed-author:BarnettSusan WSW,
pubmed-author:BlanchardJamesJ,
pubmed-author:BohmRudolphR,
pubmed-author:BucknerClarisaC,
pubmed-author:GettieAgegnehuA,
pubmed-author:GinesLeoned GLG,
pubmed-author:SafritJeffrey TJT,
pubmed-author:SaundersCheryl JCJ,
pubmed-author:SrivastavaIndreshI,
pubmed-author:StamatatosLeonidasL,
pubmed-author:VojtechLuciaL
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
320
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
167-80
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:15003872-AIDS Vaccines,
pubmed-meshheading:15003872-Animals,
pubmed-meshheading:15003872-B-Lymphocytes,
pubmed-meshheading:15003872-CD4-Positive T-Lymphocytes,
pubmed-meshheading:15003872-Glycoproteins,
pubmed-meshheading:15003872-HIV Antibodies,
pubmed-meshheading:15003872-HIV-1,
pubmed-meshheading:15003872-Immunity, Active,
pubmed-meshheading:15003872-Macaca mulatta,
pubmed-meshheading:15003872-Receptors, CCR5,
pubmed-meshheading:15003872-Recombination, Genetic,
pubmed-meshheading:15003872-Simian Acquired Immunodeficiency Syndrome,
pubmed-meshheading:15003872-Simian immunodeficiency virus,
pubmed-meshheading:15003872-Time Factors,
pubmed-meshheading:15003872-Vaccination,
pubmed-meshheading:15003872-Vaccines, Subunit,
pubmed-meshheading:15003872-Viral Envelope Proteins
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV.
|
|
pubmed:affiliation |
Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
